Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’

被引：0
|
作者：
Amir Ansaripour
Carin A. Uyl-de Groot
W. Ken Redekop
机构：
[1] Erasmus University Rotterdam,Institute for Medical Technology Assessment, Erasmus School of Health Policy and Management
来源：
PharmacoEconomics | 2018年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：381 / 382
页数：1
相关论文
共 50 条
  • [41] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    [J]. LANCET, 2005, 366 (9486): : 634 - 634
  • [42] Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?
    Santini, Daniele
    Vincenzi, Bruno
    Tonini, Giuseppe
    [J]. WOMENS HEALTH, 2006, 2 (01) : 1 - 3
  • [43] Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
    Genuino, Anne Julienne
    Chaikledkaew, Usa
    Guerrero, Anna Melissa
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    [J]. BMC HEALTH SERVICES RESEARCH, 2019, 19 (01)
  • [44] Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
    Anne Julienne Genuino
    Usa Chaikledkaew
    Anna Melissa Guerrero
    Thanyanan Reungwetwattana
    Ammarin Thakkinstian
    [J]. BMC Health Services Research, 19
  • [45] Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore
    Cheng, Li-Jen
    Loke, Lydia
    Lim, Elaine Hsuen
    Pearce, Fiona
    Aziz, Mohamed Ismail Abdul
    Ng, Kwong
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 449 - 456
  • [46] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS PERTUZUMAB WITH TRASTUZUMAB FOR CHINESE PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER
    Guan, X.
    Li, H. C.
    Xia, Y.
    Yang, Q.
    Ma, A. X.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S372 - S372
  • [47] COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE NEOADJUVANT TREATMENT OF HER2-POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER IN CHINA
    Li, H.
    Guan, X.
    Chen, Q.
    Hao, C.
    Li, J.
    Wang, Y.
    Zhang, J.
    Li, K.
    Liu, C.
    Chu, Y.
    Ma, A.
    [J]. VALUE IN HEALTH, 2019, 22 : S480 - S480
  • [48] A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB REGIMENS IN EARLY HER2/NEU-POSITIVE BREAST CANCER IN COLOMBIA
    Buendia Rodriguez, J. A.
    Vallejos, C.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A449 - A449
  • [49] COST-EFFECTIVENESS OF ADJUVANT THERAPY WITH TRASTUZUMAB IN THE TREATMENT OF EARLY BREAST CANCER (EBC) IN ROMANIA
    Grecea, D.
    Baculea, S.
    Radu, P. C.
    Pana, B.
    Szkultecka-Debek, M.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A42 - A42
  • [50] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+breast cancer.
    Garrison, L. P., Jr.
    Perez, E. A.
    Dueck, A.
    Lalla, D.
    Paton, V.
    Lubeck, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 306S - 306S
12345